12-Digit NDC Transition Is Underway: What Healthcare Organizations Should Do Now

When the FDA’s final rule (published on March 5, 2026), takes effect on March 7, 2033, every FDA-assigned National Drug Code (NDC) will move to uniform 12-digit format. Although the deadline is seven years away, the transition will require coordinated changes across claims, rebates, formularies, dispensing, inventory, drug data, labeling, barcodes and supply-chain systems. Organizations that begin assessing those dependencies now will be better positioned to avoid rejected transactions, data mismatches, operational disruption and costly rework.

RxLogic recognizes the impact of this change as it is deeply embedded in claims adjudication, rebate calculations, dispensing and supply chain systems. Our team of experts cautions industry partners not to wait until the deadline to start paying attention as across the healthcare ecosystem, that preparation work is already underway.

An Update on What’s Changing

For decades, the FDA has assigned NDCs as 10-digit numbers in one of three segment configurations, a variability that forced the industry to adopt an 11-digit “workaround” for HIPAA-covered transactions like claims and reimbursement. That mismatch between the FDA’s native format and the industry’s operational standard has been a persistent source of conversion logic, mapping tables and error-prone data transformations.

The final rule resolves that inconsistency by establishing a single 12-digit format: a 6-digit labeler code, a 4-digit product code and a 2-digit package code. Existing 10-digit codes will convert automatically through leading-zero padding rather than reassignment, meaning no new NDC is technically being created. The rule also updates barcode regulations to permit nonlinear, two-dimensional barcodes alongside traditional linear ones. Notably, beginning in 2033, a single 2D data matrix barcode may be able to satisfy both the NDC label requirement and the product-identifier requirements of the Drug Supply Chain Security Act, encoding the NDC, serial number, lot number and expiration date together.

Beyond format consistency, the change addresses a more urgent operational concern: NDC exhaustion. The FDA has been approaching the limits of its five-digit labeler code pool, a risk underscored by 2020, when the agency assigned roughly seven years’ worth of typical labeler codes in a single year amid the COVID-19 response. Expanding to a six-digit labeler segment significantly increases the available code space and reduces the risk of code reuse, which can otherwise create serious downstream pricing and claims-identification errors.

Projected Timeline

The FDA built an intentionally long runway into the rule. From March 2026 through March 2033, the agency will continue assigning 10-digit NDCs while stakeholders use the window to update systems and processes. On March 7, 2033, the FDA begins assigning 12-digit codes and automatically converts existing NDCs across its data systems. A three-year labeling transition follows, through March 2036, during which the FDA will not object to continued use of 10-digit NDCs on labels, provided downstream systems can handle both formats.

Cross-Sector Collaboration Already Materializing

The scale of coordination this transition requires was on full display in May, when more than 60 professionals from across the healthcare ecosystem gathered in Washington, D.C., for a two-day implementation workshop hosted by Leavitt Partners, an HMA Company. The room included drug manufacturers, distributors, wholesalers, technology providers, PBMs, health plans, pharmacy chains, standards organizations and compendium companies, alongside federal representatives from the FDA, CDC, DEA and NABP.

The workshop’s first day focused on building a shared understanding of the rule and surfacing cross-sector risks, including practical questions like how the industry will determine whether a 10-digit-labeled product entered commerce before or after the 2033 cutover, and how scanning infrastructure in pharmacies and hospitals will need to evolve to support 2D data matrix barcodes. The second day shifted toward roadmap-building: working through how 10-digit and 12-digit products will coexist during the transition, the role of crosswalks between formats, and the reality that some 10-digit products may remain in circulation well beyond 2036.

One theme that surfaced repeatedly: this rule, on its own, does not change the HIPAA-mandated 11-digit NDC format that governs pharmacy claims transactions. Because the HIPAA transaction standard falls under CMS’s regulatory authority, continued engagement with CMS will be essential so that claims processing, adjudication, rebate management and formulary systems can align with the FDA’s new format on a compatible timeline.

An Enduring Resource for the Industry

Recognizing that no single organization can manage this transition alone, the NDC Coordination and Implementation Forum has established a Quarterly Forum bringing together stakeholders from across the ecosystem, pharmacy systems, wholesalers, manufacturers, PBMs, payers, technology vendors, standards organizations and government, to track implementation progress, share updates from key partners and identify emerging risks before they create disruption or costly rework.

Upcoming sessions give pharmacy stakeholders, health plans and industry partners a low-effort way to stay current:

• Q4 Quarterly Forum: Tuesday, December 8 and Wednesday, December 9, 2026, 1-3 p.m. ET each day

Registration is available at www.NDCForum.org/ndcquarterlyforums

Why Early Engagement Matters

Seven years seems like a generous runway to implement a change of this magnitude, but the breadth of systems touched by this change, from claims adjudication and rebate calculations to inventory management and supply chain verification, means the organizations that start now will be far better positioned than those that wait.

The FDA has signaled that the 2033 effective date will not move. For pharmacy, PBM and health plan stakeholders in particular, staying close to both the FDA’s guidance and CMS’s forthcoming rulemaking on the HIPAA standard will be critical to a smooth transition.

RxLogic is actively assessing the implications of the 12-digit NDC across our own platforms, including claims adjudication, rebate administration and real-time benefit transactions. As a member of the NDC Coordination and Implementation Forum, RxLogic is also directly engaged in the industry collaboration shaping the implementation roadmap. Billy Buckles, Senior Vice President, Business Development & Implementation at RxLogic, serves on the Forum’s Steering Committee/advising and helping guide the industry’s collective approach to this transition.

We encourage clients and partners to stay engaged through resources like the Forum’s Quarterly Forum as the roadmap continues to develop.